Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Myriad Genetics Inc
(NQ:
MYGN
)
25.47
+0.22 (+0.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,134,946
Open
25.16
Bid (Size)
24.90 (10)
Ask (Size)
26.85 (1)
Prev. Close
25.25
Today's Range
24.99 - 25.95
52wk Range
13.82 - 25.95
Shares Outstanding
90,500,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Today 6:00 EDT
Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today.
Via
InvestorPlace
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 08, 2024
Via
Benzinga
Performance
YTD
+34.05%
+34.05%
1 Month
+25.72%
+25.72%
3 Month
+15.77%
+15.77%
6 Month
+54.83%
+54.83%
1 Year
+11.03%
+11.03%
More News
Read More
Myriad Genetics: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Via
Benzinga
Myriad Genetics Earnings Preview
February 26, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Myriad Genetics Through Analyst Insights
January 29, 2024
Via
Benzinga
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
May 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 08, 2024
Via
Benzinga
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
May 07, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
May 07, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
April 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
April 17, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
April 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
April 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
March 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
March 20, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the
February 27, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
February 27, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
February 15, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
February 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
January 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
January 18, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
January 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.